{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Long S"],"funding":["Program for Top Scientific and Technological Talents in Guizhou Province","Natural Science Foundation of Guizhou Province","Key Program for Science and Technology of Guizhou Province","National Natural Science Foundation of China"],"pagination":["185"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8088708"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(1)"],"pubmed_abstract":["Background
Cetuximab has been approved for use for first-line treatment of patients with wild-type KRAS metastatic colorectal cancer (CRC). However, treatment with cetuximab has shown limited efficacy as a CRC monotherapy. In addition, natural killer (NK) cell function is known to be severely attenuated in cancer patients. The goal of this study was to develop a new strategy to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by NK cells, in combination with cetuximab against CRC cells.Methods
Ex vivo expanded NK cells were stimulated with reovirus, and reovirus-activated NK cells mediated ADCC assay were performed on CRC cells in combination with cetuximab. The synergistic antitumor effects of reovirus-activated NK cells and cetuximab were tested on DL"],"journal":["Journal of translational medicine"],"pubmed_title":["Reovirus enhances cytotoxicity of natural killer cells against colorectal cancer via TLR3 pathway."],"pmcid":["PMC8088708"],"funding_grant_id":["ZK(2021)012]","81860542","(2019)5663","KY (2018)049"],"pubmed_authors":["Wang N","Ouyang W","Gu Y","He Z","An Y","Lin X","Chen X","Wang X","Liao C","Long S","Zhao X"],"additional_accession":[]},"is_claimable":false,"name":"Reovirus enhances cytotoxicity of natural killer cells against colorectal cancer via TLR3 pathway.","description":"Background
Cetuximab has been approved for use for first-line treatment of patients with wild-type KRAS metastatic colorectal cancer (CRC). However, treatment with cetuximab has shown limited efficacy as a CRC monotherapy. In addition, natural killer (NK) cell function is known to be severely attenuated in cancer patients. The goal of this study was to develop a new strategy to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by NK cells, in combination with cetuximab against CRC cells.Methods
Ex vivo expanded NK cells were stimulated with reovirus, and reovirus-activated NK cells mediated ADCC assay were performed on CRC cells in combination with cetuximab. The synergistic antitumor effects of reovirus-activated NK cells and cetuximab were tested on DL","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2026-05-08T15:56:50.685Z","creation":"2025-02-19T03:43:36.819Z"},"accession":"S-EPMC8088708","cross_references":{"pubmed":["33933132"],"doi":["10.1186/s12967-021-02853-y"]}}